MPM BioVentures 2014, L.P. - Sep 9, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
Stock symbol
ITOS
Transactions as of
Sep 9, 2021
Transactions value $
-$1,632,261
Form type
4
Date filed
9/13/2021, 07:01 PM
Previous filing
Sep 8, 2021
Next filing
Sep 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale -$658K -22.7K -0.63% $28.97 3.57M Sep 9, 2021 See Footnote F1, F2, F3, F4
transaction ITOS Common Stock Sale -$188K -6.76K -0.19% $27.86 3.56M Sep 10, 2021 See Footnote F1, F5, F6, F7
transaction ITOS Common Stock Sale -$195K -6.77K -0.19% $28.73 3.56M Sep 10, 2021 See Footnote F1, F8, F9, F10
transaction ITOS Common Stock Sale -$591K -21.4K -0.6% $27.64 3.53M Sep 13, 2021 See Footnote F1, F11, F12, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
F2 The shares were sold as follows: 13,539 by MPM BioVentures 2014, L.P. ("BV 2014"), 466 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,551 by MPM BioVentures 2018, L.P. ("BV 2018") and 169 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.29 to $29.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The shares are held as follows: 2,029,971 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 69,871 by AM BV2014, 1,282,086 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 25,302 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5 The shares were sold as follows: 4,027 by BV 2014, 139 by AM BV2014, 2,544 by BV 2018 and 50 by AM BV2018.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.455 to $28.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The shares are held as follows: 2,025,944 by BV 2014, 107,713 by BV 2014(B), 69,732 by AM BV2014, 1,279,542 by BV 2018, 54,213 by BV 2018(B) and 25,252 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F8 The shares were sold as follows: 4,034 by BV 2014, 139 by AM BV2014, 2,547 by BV 2018 and 51 by AM BV2018.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.46 to $28.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The shares are held as follows: 2,021,910 by BV 2014, 107,713 by BV 2014(B), 69,593 by AM BV2014, 1,276,995 by BV 2018, 54,213 by BV 2018(B) and 25,201 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F11 The shares were sold as follows: 12,740 by BV 2014, 439 by AM BV2014, 8,046 by BV 2018 and 159 by AM BV2018.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $27.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F13 The shares are held as follows: 2,009,170 by BV 2014, 107,713 by BV 2014(B), 69,154 by AM BV2014, 1,268,949 by BV 2018, 54,213 by BV 2018(B) and 25,042 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.